We are live on ! Find out more
GBIO

Generation Bio

Delisted

GBIO was delisted on the 6th of February, 2026.

2 hedge funds and large institutions have $53.3K invested in Generation Bio in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% less ownership

Funds ownership: 64%0% (-64%)

96% less funds holding

Funds holding: 482 (-46)

100% less capital invested

Capital invested by funds: $24.5M → $53.3K (-$24.5M)

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 45

Holders
2
Holders Change
-46
Holders Change %
-95.83%
% of All Funds
0.02%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
Increased
1
Reduced
Closed
45
Calls
Puts
Net Calls
Net Calls Change

GBIO Hedge Fund Activity: Q1 2026 in Review

2 of the 8,159 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q1 2026, worth a combined $53.3K — down 100% from $24.5M a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of GBIO and 0 opened new positions — a net loss of 45 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Accent Capital Management, adding an estimated $195. The largest seller was Atlas Venture Life Science Advisors, exiting entirely with an estimated $4.7M sold.

  • 2 institutional investors held Generation Bio (GBIO) as of Q1 2026, down from 48 in Q4 2025.
  • Funds reported $53.3K of Generation Bio stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Generation Bio positions in Q1 2026 and 45 closed out, a net change of -45 holders.
  • The largest Generation Bio buyer in Q1 2026 was Accent Capital Management, an estimated $195 added.
  • The largest Generation Bio seller in Q1 2026 was Atlas Venture Life Science Advisors, an estimated $4.7M sold.

Based on aggregated 13F filings for Q1 2026.